BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Netti GS, Franzin R, Stasi A, Spadaccino F, Dello Strologo A, Infante B, Gesualdo L, Castellano G, Ranieri E, Stallone G. Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers. Cells 2021;10:2426. [PMID: 34572075 DOI: 10.3390/cells10092426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Song J, Yang Z, Zhao J, Wang J, Sun C, Zhu X. Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies. Biomarkers 2023;:1-14. [PMID: 36598268 DOI: 10.1080/1354750X.2023.2164906] [Reference Citation Analysis]
2 Zhou Z, Zhou X, Yang Y, Wang L, Wu Z. Pan-Cancer Analysis of Pentraxin 3: A Potential Biomarker of COVID-19. Cancers 2022;14:4438. [DOI: 10.3390/cancers14184438] [Reference Citation Analysis]
3 Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO. Cellular senescence: the good, the bad and the unknown. Nat Rev Nephrol 2022. [PMID: 35922662 DOI: 10.1038/s41581-022-00601-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Reddy R, Mintz J, Golan R, Firdaus F, Ponce R, Van Booven D, Manoharan A, Issa I, Blomberg BB, Arora H. Antibody Diversity in Cancer: Translational Implications and Beyond. Vaccines 2022;10:1165. [DOI: 10.3390/vaccines10081165] [Reference Citation Analysis]
5 Rahmati Nezhad P, Riihilä P, Knuutila JS, Viiklepp K, Peltonen S, Kallajoki M, Meri S, Nissinen L, Kähäri VM. Complement Factor D Is a Novel Biomarker and Putative Therapeutic Target in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2022;14:305. [PMID: 35053469 DOI: 10.3390/cancers14020305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]